LivaNova PLC (NASDAQ:LIVN) Shares Bought by Credit Suisse AG

Credit Suisse AG raised its position in LivaNova PLC (NASDAQ:LIVN) by 8.4% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 68,831 shares of the company’s stock after acquiring an additional 5,351 shares during the period. Credit Suisse AG owned approximately 0.13% of LivaNova worth $3,000,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in LIVN. Great Lakes Advisors LLC acquired a new stake in shares of LivaNova in the first quarter valued at about $2,589,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of LivaNova by 320.6% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 78,117 shares of the company’s stock worth $3,404,000 after buying an additional 59,545 shares in the last quarter. Tekla Capital Management LLC purchased a new stake in shares of LivaNova during the first quarter worth about $2,784,000. US Bancorp DE grew its holdings in shares of LivaNova by 14.0% during the first quarter. US Bancorp DE now owns 1,840 shares of the company’s stock worth $80,000 after buying an additional 226 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of LivaNova during the first quarter worth about $529,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Stock Up 0.5 %

Shares of NASDAQ:LIVN opened at $55.85 on Friday. The company has a current ratio of 3.27, a quick ratio of 2.73 and a debt-to-equity ratio of 0.46. The company has a fifty day simple moving average of $54.20 and a 200 day simple moving average of $49.09. The firm has a market cap of $3.01 billion, a PE ratio of -30.69 and a beta of 0.91. LivaNova PLC has a 12-month low of $40.26 and a 12-month high of $59.86.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, July 26th. The company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.54 by $0.24. LivaNova had a negative net margin of 8.94% and a positive return on equity of 11.60%. The business had revenue of $293.90 million during the quarter, compared to analyst estimates of $265.05 million. During the same quarter in the previous year, the firm earned $0.53 earnings per share. The business’s revenue was up 15.6% compared to the same quarter last year. On average, equities research analysts anticipate that LivaNova PLC will post 2.39 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on LIVN shares. Mizuho boosted their target price on shares of LivaNova from $53.00 to $60.00 in a report on Thursday, July 27th. Robert W. Baird boosted their target price on shares of LivaNova from $56.00 to $62.00 in a report on Thursday, July 27th. Barclays lifted their price target on shares of LivaNova from $51.00 to $57.00 and gave the company an “equal weight” rating in a research report on Thursday, July 27th. StockNews.com assumed coverage on shares of LivaNova in a research report on Thursday, August 17th. They set a “buy” rating on the stock. Finally, TheStreet raised shares of LivaNova from a “d+” rating to a “c-” rating in a research report on Monday, July 17th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, LivaNova currently has a consensus rating of “Moderate Buy” and an average price target of $67.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.